BR112018068898A2 - anticorpo ou fragmento e seus usos, animal transgênico, hibridoma, vetor, composição farmacêutica e seu uso, método para modular uma doença, método para tratar perda de peso, método para modular atividade - Google Patents

anticorpo ou fragmento e seus usos, animal transgênico, hibridoma, vetor, composição farmacêutica e seu uso, método para modular uma doença, método para tratar perda de peso, método para modular atividade

Info

Publication number
BR112018068898A2
BR112018068898A2 BR112018068898-3A BR112018068898A BR112018068898A2 BR 112018068898 A2 BR112018068898 A2 BR 112018068898A2 BR 112018068898 A BR112018068898 A BR 112018068898A BR 112018068898 A2 BR112018068898 A2 BR 112018068898A2
Authority
BR
Brazil
Prior art keywords
modulating
hybridoma
antibody
fragment
vector
Prior art date
Application number
BR112018068898-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Shen Wenyan
Tang Jie
Wang Yan
Matern Hugo
Original Assignee
Ngm Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals, Inc. filed Critical Ngm Biopharmaceuticals, Inc.
Publication of BR112018068898A2 publication Critical patent/BR112018068898A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112018068898-3A 2016-03-31 2017-03-03 anticorpo ou fragmento e seus usos, animal transgênico, hibridoma, vetor, composição farmacêutica e seu uso, método para modular uma doença, método para tratar perda de peso, método para modular atividade BR112018068898A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662316516P 2016-03-31 2016-03-31
US62/316,516 2016-03-31
PCT/US2017/020654 WO2017172260A1 (en) 2016-03-31 2017-03-03 Binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112018068898A2 true BR112018068898A2 (pt) 2019-01-22

Family

ID=59966343

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068898-3A BR112018068898A2 (pt) 2016-03-31 2017-03-03 anticorpo ou fragmento e seus usos, animal transgênico, hibridoma, vetor, composição farmacêutica e seu uso, método para modular uma doença, método para tratar perda de peso, método para modular atividade

Country Status (18)

Country Link
US (4) US10174119B2 (https=)
EP (1) EP3436068A4 (https=)
JP (3) JP7021099B2 (https=)
KR (2) KR102630655B1 (https=)
CN (2) CN109715206B (https=)
AU (3) AU2017241161C1 (https=)
BR (1) BR112018068898A2 (https=)
CA (1) CA3016035A1 (https=)
CL (1) CL2018002687A1 (https=)
CO (1) CO2018009995A2 (https=)
IL (1) IL261666B2 (https=)
MX (2) MX2018011503A (https=)
MY (1) MY194669A (https=)
PE (1) PE20190126A1 (https=)
PH (1) PH12018501882A1 (https=)
SG (1) SG11201807279QA (https=)
TW (2) TWI897070B (https=)
WO (1) WO2017172260A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
KR20190059312A (ko) * 2016-10-12 2019-05-30 얀센 바이오테크 인코포레이티드 Gdf15-유사 생물학적 활성의 조절제에 대한 스크리닝 방법
EP3833974A2 (en) * 2018-08-10 2021-06-16 Novartis AG Gfral extracellular domains and methods of use
WO2020163502A1 (en) 2019-02-05 2020-08-13 The Trustees Of The University Of Pennsylvania Peptide ligands of the gdnf family receptor a-like (gfral) receptor
WO2020227640A1 (en) * 2019-05-08 2020-11-12 Agilvax, Inc. Compositions and methods related to xct antibodies
US12594330B2 (en) 2019-06-04 2026-04-07 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
WO2021050978A1 (en) * 2019-09-11 2021-03-18 University Of Cincinnati Treatment of skin blistering diseases using antibodies
US12398211B2 (en) 2020-06-04 2025-08-26 Daegu Gyeongbuk Institute Of Science And Technology GFRAL-antagonistic antibody and use thereof
KR102708796B1 (ko) 2020-06-04 2024-09-26 재단법인대구경북과학기술원 Gfral 길항 항체 및 이의 용도
US20240124606A1 (en) * 2021-02-22 2024-04-18 Northwestern University Anti-cd73 monoclonal antibodies
WO2022207785A1 (en) * 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
US20240182585A1 (en) 2021-03-31 2024-06-06 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
CN117693525A (zh) * 2021-06-30 2024-03-12 上海津曼特生物科技有限公司 抗gfral抗体及其应用
IL310535A (en) 2021-08-10 2024-03-01 Byomass Inc Anti-gdf15 antibodies, compositions and uses thereof
WO2023039359A1 (en) 2021-09-10 2023-03-16 Ngm Biopharmaceuticals, Inc. Methods of treating cancer and tumor-related weight loss and cachexia
EP4406972A4 (en) * 2021-09-24 2025-12-31 Daegu Gyeongbuk Inst Science & Tech GFRAL ANTAGONIST ANTIBODY WITH IMPROVED AFINITY, AND ITS USE
KR102864956B1 (ko) 2021-09-24 2025-09-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
AU2023216348A1 (en) * 2022-02-03 2024-06-20 Igm Biosciences, Inc. Anti-cd38 binding molecules and uses thereof
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
JP2025511146A (ja) * 2022-03-28 2025-04-15 コーヘラス・バイオサイエンシーズ・インコーポレイテッド 抗ｉｌｔ４組成物および方法
CN118580334A (zh) * 2023-03-03 2024-09-03 北京志道生物科技有限公司 一种多肽分子
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica
TW202506184A (zh) 2023-07-31 2025-02-16 美商恩格姆生物製藥公司 使用抗ｇｆｒａｌ抗體治療噁心及嘔吐病症之方法
CN117209596B (zh) * 2023-09-01 2024-11-26 中国农业科学院兰州兽医研究所 抗非洲猪瘟病毒p72蛋白中和活性单克隆抗体2c9及其应用
WO2025179086A1 (en) * 2024-02-23 2025-08-28 Children's National Medical Center Anti-ret antibodies as cancer therapeutics and diagnostic tools
WO2025244462A1 (ko) * 2024-05-24 2025-11-27 한국과학기술원 Gfral을 표적으로 하는 단일클론 항체 및 이의 용도

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994003599A1 (fr) 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
US6180602B1 (en) 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
JPH07258293A (ja) 1994-03-23 1995-10-09 Asahi Chem Ind Co Ltd 新規な蛋白質ならびにその製造方法
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
WO1996018730A1 (en) 1994-12-15 1996-06-20 Human Genome Sciences, Inc. Prostatic growth factor
ES2324433T3 (es) 1995-06-22 2009-08-06 St Vincent's Hospital Sydney Limited Tgf-beta novedoso similar a citocina.
US6696259B1 (en) 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
KR19990067508A (ko) 1995-11-13 1999-08-25 한누 사리올라 신경교 세포주 유래 신경영양성 인자 수용체
US6524802B1 (en) 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
JP2001500732A (ja) 1996-09-11 2001-01-23 オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド 前立腺がんを治療するためのＴＮＦ―β様タンパク質、ならびに関連する核酸分子、医薬組成物および方法
CA2289116A1 (en) * 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
KR20010012826A (ko) 1997-05-22 2001-02-26 세파론, 인코포레이티드 신경교 세포주-유래 향신경성 인자 수용체
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
WO2000005259A1 (en) 1998-07-23 2000-02-03 Smithkline Beecham Corporation Secreted cysteine rich protein-6 (scrp-6)
WO2000020867A1 (en) 1998-10-01 2000-04-13 Alexey Vladimirovich Titievsky A novel ret-independent signaling pathway for gdnf
US6905817B1 (en) 1998-10-01 2005-06-14 Licestia Ltd. Ret-independent signaling pathway for GDNF
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2002543841A (ja) 1999-05-17 2002-12-24 バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー ＴＧＦ−βスーパーファミリーの新規のメンバーであるＧＤＦ―１５の神経保護特性
US6866851B1 (en) 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
ATE470863T1 (de) 2000-04-20 2010-06-15 St Vincents Hosp Sydney Diagnostischer assay mit makrophagenhemmendem zytokin-1 (mic-1)
AU2001288770A1 (en) 2000-09-08 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
WO2002062999A2 (en) 2000-12-29 2002-08-15 Curagen Corporation Proteins and nucleic acids encoding same
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
AU2002250293B2 (en) 2001-03-09 2007-10-11 Arnason, Barry G. Mr Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
DK1385882T3 (da) 2001-05-11 2008-02-11 Amgen Inc Peptider og relaterede molekyler, der binder til TALL-1
GB0115195D0 (en) 2001-06-21 2001-08-15 Bae Systems Plc Split-pin drill jig
US20030053431A1 (en) 2001-09-10 2003-03-20 Lila Madour Method for performing handoff in a radio telecommunications network
US20060253913A1 (en) 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US7642242B2 (en) 2002-03-05 2010-01-05 Genentech, Inc. PRO34128 polypeptides
US20100285016A1 (en) 2002-03-05 2010-11-11 Genentech, Inc. PRO34128 nucleic acids
CA2478369A1 (en) * 2002-03-05 2003-09-18 Genentech, Inc. Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
EP1575512A4 (en) 2002-11-08 2007-08-29 Barnes Jewish Hospital METHOD AND COMPOSITIONS FOR THE EPITHELIAL CELL DIFFERENTIATION IN THE PROSTATE
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
CN1241941C (zh) * 2003-11-21 2006-02-15 中国科学院上海生命科学研究院 一种促进神经分化和抗细胞凋亡的蛋白质及其编码基因
EP2441466B1 (en) 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited MIC-1 inhibiting agent
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
WO2006078161A1 (en) 2005-01-24 2006-07-27 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
TWI428448B (zh) 2006-03-24 2014-03-01 Syntonix Pharmaceuticals Inc 作為第九因子（ｆａｃｔｏｒ ｉｘ）原肽處理酶之ｐｃ５
US8974748B2 (en) 2007-04-05 2015-03-10 Corning Incorporated Dual inlet microchannel device and method for using same
CA2649387A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US7754689B2 (en) 2006-06-02 2010-07-13 Wyeth Llc Finger-1 peptide analogs of the TGF-β superfamily
JP2009544697A (ja) 2006-07-26 2009-12-17 ペプスキャン システムズ ベー．フェー． 免疫原性化合物及びタンパク質擬態物
MX2009000914A (es) 2006-08-04 2009-06-18 Hannover Med Hochschule Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento.
RU2461569C2 (ru) * 2006-10-19 2012-09-20 Дженентек, Инк. Агонистические антитела против notch3 и их применение для лечения notch3-ассоциированных заболеваний
CN101808672B (zh) 2007-04-25 2013-05-01 干细胞旋转股份公司 干细胞系、其应用以及培养方法
BRPI0814465B1 (pt) 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN101896192A (zh) 2007-10-09 2010-11-24 圣文森特医院悉尼有限公司 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法
ES2543985T3 (es) 2007-10-22 2015-08-26 St Vincent's Hospital Sydney Limited Métodos de pronóstico
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
WO2009087190A1 (en) 2008-01-08 2009-07-16 Roche Diagnostics Gmbh Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15
CA2711503A1 (en) 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
US8718994B2 (en) 2008-04-09 2014-05-06 Transtech Pharma, Llc Ligands for the GLP-1 receptor and methods for discovery thereof
WO2009141357A1 (en) 2008-05-20 2009-11-26 Roche Diagnostics Gmbh Gdf-15 as biomarker in type 1 diabetes
JP2011528115A (ja) 2008-07-14 2011-11-10 エフ．ホフマン−ラ ロシュ アーゲー 心不全を有する患者の診断、モニター及び治療の選択のためのマルチマーカーパネル
WO2010019263A2 (en) 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
JP5444363B2 (ja) 2008-10-31 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 慢性腎疾患における予後判定の方法
EP2350265B1 (en) 2008-10-31 2019-04-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
EP2211182A1 (en) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
AU2010213575B2 (en) 2009-02-12 2013-11-14 Stryker Corporation Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease
GB0902737D0 (en) 2009-02-19 2009-04-01 Univ Gent GDF15 as a differential marker for spondyloarthropathy
JP5841845B2 (ja) 2009-02-24 2016-01-13 ソーク・インステチュート・フォー・バイオロジカル・スタディーズＳａｌｋ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｌｏｇｉｃａｌ Ｓｔｕｄｉｅｓ ＴＧＦ−βスーパーファミリーのデザイナーリガンド
WO2010129503A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
JP2012532608A (ja) 2009-07-08 2012-12-20 アムジェン インコーポレイテッド ＣＨ３ドメイン界面操作を通じた、安定でそして凝集しない抗体Ｆｃ分子の設計
US20130323835A1 (en) 2009-07-15 2013-12-05 Zirus, Inc. Mammalian Genes Involved in Infection
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
EP2496601B1 (en) 2009-11-05 2017-06-07 F. Hoffmann-La Roche AG Methods and composition for secretion of heterologous polypeptides
WO2011064758A2 (en) 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
US20120321557A1 (en) 2010-02-26 2012-12-20 Forerunner Pharma Research Co., Ltd. Anti-icam3 antibody and use thereof
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
JP5791335B2 (ja) 2010-04-07 2015-10-07 花王株式会社 オルガノポリシロキサン化合物の製造方法
US20130202564A1 (en) 2010-04-09 2013-08-08 University Of Southern California Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration
EP2383571A1 (en) 2010-05-02 2011-11-02 Prof. Hess Medical Consulting GmbH Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer
CN108387744A (zh) 2010-08-26 2018-08-10 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
WO2013012648A1 (en) * 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
EP3683228A3 (en) 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP2863910B1 (en) 2012-06-20 2020-03-11 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
WO2014000042A1 (en) 2012-06-27 2014-01-03 Prince Henry's Institute Of Medical Research COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
UY34905A (es) * 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
HK1210192A1 (en) * 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
PE20150645A1 (es) 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
RS59045B1 (sr) 2012-09-26 2019-08-30 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15)
WO2014066590A1 (en) 2012-10-24 2014-05-01 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
US20150376294A1 (en) 2012-12-03 2015-12-31 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
ES2791183T3 (es) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
DE102013100322A1 (de) 2013-01-14 2014-07-17 Claas Selbstfahrende Erntemaschinen Gmbh Schneidwerk
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
WO2014140374A2 (en) * 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
MX2015016978A (es) 2013-06-10 2016-04-25 Merck Sharp & Dohme Proteinas de union a antigeno neutralizantes de citomegalovirus.
US9862752B2 (en) 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
AU2015296640B2 (en) 2014-07-30 2020-05-21 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
CN108697795A (zh) 2016-02-29 2018-10-23 伊莱利利公司 Gfral受体疗法
US20170299608A1 (en) 2016-03-04 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
KR20190059312A (ko) 2016-10-12 2019-05-30 얀센 바이오테크 인코포레이티드 Gdf15-유사 생물학적 활성의 조절제에 대한 스크리닝 방법
CN112912395B (zh) 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法
US12398211B2 (en) 2020-06-04 2025-08-26 Daegu Gyeongbuk Institute Of Science And Technology GFRAL-antagonistic antibody and use thereof
EP4304647A1 (en) 2021-03-08 2024-01-17 MedImmune, LLC Antibodies directed against gdf-15
US20240182585A1 (en) 2021-03-31 2024-06-06 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
WO2022207785A1 (en) 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
WO2023039359A1 (en) 2021-09-10 2023-03-16 Ngm Biopharmaceuticals, Inc. Methods of treating cancer and tumor-related weight loss and cachexia

Also Published As

Publication number Publication date
MX2024011328A (es) 2024-11-08
WO2017172260A8 (en) 2017-12-28
CN109715206B (zh) 2023-11-07
IL261666A (en) 2018-10-31
JP2022088355A (ja) 2022-06-14
JP2019513018A (ja) 2019-05-23
US12180289B2 (en) 2024-12-31
AU2017241161C1 (en) 2026-03-12
JP2024156852A (ja) 2024-11-06
JP7021099B2 (ja) 2022-02-18
US20170306031A1 (en) 2017-10-26
JP7610541B2 (ja) 2025-01-08
PE20190126A1 (es) 2019-01-17
KR102370762B1 (ko) 2022-03-04
US20250188174A1 (en) 2025-06-12
KR20220032645A (ko) 2022-03-15
US10174119B2 (en) 2019-01-08
US20220073627A1 (en) 2022-03-10
CN117986363A (zh) 2024-05-07
NZ745635A (en) 2024-03-22
CO2018009995A2 (es) 2018-12-14
US20190092866A1 (en) 2019-03-28
US10975154B2 (en) 2021-04-13
AU2022224794B2 (en) 2025-07-03
EP3436068A4 (en) 2020-01-15
NZ785098A (en) 2025-09-26
CA3016035A1 (en) 2017-10-05
EP3436068A1 (en) 2019-02-06
CN109715206A (zh) 2019-05-03
MY194669A (en) 2022-12-12
TWI897070B (zh) 2025-09-11
SG11201807279QA (en) 2018-09-27
IL261666B1 (en) 2024-05-01
RU2018132739A3 (https=) 2020-09-02
IL261666B2 (en) 2024-09-01
MX2018011503A (es) 2018-11-09
AU2025234197A1 (en) 2025-10-16
WO2017172260A1 (en) 2017-10-05
KR20180130524A (ko) 2018-12-07
AU2017241161B2 (en) 2022-05-26
PH12018501882A1 (en) 2019-01-28
RU2018132739A (ru) 2020-04-30
TW201809011A (zh) 2018-03-16
KR102630655B1 (ko) 2024-01-30
AU2022224794A1 (en) 2022-09-22
TW202423985A (zh) 2024-06-16
TWI815793B (zh) 2023-09-21
CL2018002687A1 (es) 2019-05-10
AU2017241161A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
BR112018068898A2 (pt) anticorpo ou fragmento e seus usos, animal transgênico, hibridoma, vetor, composição farmacêutica e seu uso, método para modular uma doença, método para tratar perda de peso, método para modular atividade
CO2018003973A2 (es) Proteínas de unión a pd-1 y métodos para usarlas
MX2025000370A (es) Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos
BR112019010943A8 (pt) Usos de um anticorpo que se liga especificamente ao domínio extracelular de tigit humano para a inibição do crescimento do tumor, composição que compreende o dito anticorpo, polinucleotídeo, vetor e célula
BR112018003794A2 (pt) composições e métodos para o tratamento da dor
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
BR112019004733A2 (pt) métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112015021979A2 (pt) Anticorpos humanos para grem1
BR112018006531A2 (pt) proteína isolada de ligação ao antígeno (abp), polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma proteína isolada de ligação ao antígeno (abp), composição farmacêutica, método para tratar ou prevenir uma doença ou condição num sujeito em necessidade deste, método para modular uma resposta imune num indivíduo em necessidade deste e kit
BR112017008710A8 (pt) Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
EA201792451A1 (ru) Антитела к ox40 и способы их применения
BR112019009316A2 (pt) anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie.
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112013028523A8 (pt) Uso de um anticorpo ou uma proteína de fusão ou um fragmento de ligação da mesma e método para a purificação de um anticorpo, uma proteína de fusão ou um fragmento de ligação da mesma de uma mistura fonte
MX377844B (es) Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
BR112019005726A8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd27 humano, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou de um fragmento de ligação ao antígeno, de tratamento de câncer e de tratamento de uma infecção ou de uma doença infecciosa, e, uso do anticorpo ou do fragmento de ligação ao antígeno
BR112015019350A2 (pt) Animal não humano, locus de imunoglobulina, e, métodos de fabricação de um animal não humano, para a obtenção de uma sequência de ácido nucleico e de fabricação de uma proteína de ligação ao antígeno
CL2011002756A1 (es) Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad.
BR112019002529A2 (pt) anticorpo isolado, composição, método para modular o equilíbrio de células t, método para tratar uma doença ou afecção tratável com terapia, método para tratar câncer, combinação de anticorpo igg1, anticorpo anti-icos, mamífero não humano transgênico, e método para produzir um anticorpo
MX2020010913A (es) Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
AR084627A1 (es) Formulacion farmaceutica que comprende una droga biofarmaceutica

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122026002676-2 PROTOCOLO 870260010547 EM 03/02/2026 19:46.O PEDIDO FOI DIVIDIDO NO BR122026002676-2 PROTOCOLO 870260010547 EM 03/02/2026 19:46.